Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.
复制标题
羟基脲诱导镰状细胞性贫血患者胎儿血红蛋白产生增加。
DOI：
10.1182/blood.v69.1.109.109
复制
发表时间：
1987
期刊：
影响因子：
20.3
通讯作者：
JW Moore
中科院分区：
文献类型：
--
作者：
Samuel Charache;G. Dover;Martha A. Moyer;JW Moore
5例镰状细胞性贫血患者接受了羟基脲（HU）治疗，以期增加胎儿血红蛋白的生成。治疗超过2年的2例患者的实验室反应令人鼓舞，并有临床改善的建议。长期HU治疗应考虑严重影响成人镰状细胞性贫血谁愿意接受什么可能是一个小的致癌风险。初步的染色体分析和对HU致染色体断裂特性的了解表明，应避免受孕和怀孕。可能需要进行药代动力学研究，以调整个体给药方案，从而避免细胞毒性。如果HU剂量是最佳的，F细胞反应可以在2至3周内看到，但在循环中建立大量F细胞可能需要一个月或更长时间。
Five patients with sickle cell anemia were treated with hydroxyurea (HU), in hopes of augmenting their production of fetal hemoglobin. Laboratory responses in two patients treated for more than 2 years were encouraging and there were suggestions of clinical improvement. Long-term HU therapy should be considered for severely affected adults with sickle cell anemia who are willing to accept what is probably a small risk of carcinogenesis. Preliminary chromosomal analysis and knowledge of the clastogenic properties of HU suggest that conception and pregnancy should be avoided. Pharmacokinetic studies will probably be necessary to adjust individual dosage schedules so that cytotoxicity is avoided. F cell responses can be seen in 2 to 3 weeks if the HU dose is optimal, but establishment of a large number of F cells in the circulation may take a month or longer.